Outcome of Board Meeting

C hance 6 November 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Outcome of the Meeting of the Board of Directors Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company (“Board”) at its meeting held today, i.e., 6 November 2026, has, inter alia, approved the following: 1. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30 September 2026 pursuant to Regulation 33 of the SEBI Listing Regulations. In this connection, we enclose herewith the following documents as Annexure - I: a) Unaudited Standalone and Consolidated Financial Results along with Statement of Assets and Liabilities and Cash Flow Statements; b) Limited Review Reports from the Statutory Auditors on the above financial results; c) Press Release on the financial results; and d) Investor Presentation. 2. Appointment of Dr. Kuber Jagdale (DIN: 12037580) as an Additional Director, designated as Chief Technical Officer & Executive Director, based on the recommendation of the Nomination and Remuneration Committee, for a period of 5 (five) years effective from 7 November 2026 till 6 November 2031, liable to retire by rotation, subject to the approval of the shareholders of the Company and such other approvals as applicable. Mr. Jagdale is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. 3. The proposed equity investment of 26% in the SPV (under incorporation) to be engaged in solar power generation for the purpose of captive consumption of the company`s plant operation. The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 for item no. 2 & 3 above, are set out in Annexure – II & III respectively. Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.l, Hyderabad Regd. Office: 215 Atrium, C-Wing, 8th Floor, 879-827, Andheri Kurla Road, Knowledge City, TSIIC, Raidurg, Hyderabad -500081, Telangana. Chakala MIDC, Andheri East, Mumbai, Maharastra -400093. Tel: +9140 2354 9414 / 3311 Tel: 022 6513999 CIN: L24299MH2018PLC422236 I Website: www.cohance.com I Company Email: reachus@cohance.com C hance The aforesaid information is also being made available on the Company's website at www.cohance.com. The Board Meeting commenced at 2:30 pm (IST) and concluded at 5:30 pm (IST). We request you to take the above on record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.l, Hyderabad Regd. Office: 215 Atrium, C-Wing, 8th Floor, 879-827, Andheri Kurla Road, Knowledge City, TSIIC, Raidurg, Hyderabad -500081, Telangana. Chakala MIDC, Andheri East, Mumbai, Maharastra -400093. Tel: +9140 2354 9414 / 3311 Tel: 022 6513999 CIN: L24299MH2018PLC422236 I Website: www.cohance.com I Company Email: reachus@cohance.com COHANCE LIFESCIENCES LIMITED (formerly known as Suven Pharmaceuticals Limited) Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Mfdco, Mumbai, Mumbai, Maharashtra, India, 400093 STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026 , In Crores PART-I STANDALONE For the quarter ended For the Half year ended For the year SI. No. PARTICULARS ended 30 September 2026 30June 2026 30 September 2025 30 September 2026 30 September 2025 31 March 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income Revenue from operations 416.69 359.89 497.79 776.58 981.37 2,030.50 Other income 20.57 12.16 26.30 32.73 39.40 44.73 Total income 437.26 372.05 524.09 809.31 1 020.77 2 075.23 2 Expenses a) Cost of materials consumed 230.20 151.90 188.19 382.10 363.35 691.27 b) Changes in inventories of finished goods and work-in-progress (94.86) (41.33) (49.81) (136.19) (78.98) (38.58) c) Employee benefits expense 117.03 96.34 95.10 213.37 198.53 380.43 d) Finance costs 3.35 2.12 5.24 5.47 12.04 22.46 e) Depreciation and amortisation expense 34.12 34.32 31.20 68.44 62.56 133.58 fl Other expenses 147.68 126.49 133.45 274.17 263.41 542.97 Total exoenses 437.52 369.84 403.37 807.36 820.91 1 732.13 3 Profit/lLossl before exceotional items & tax 11-21 10.261 2.21 120.72 1.95 199.86 343.10 4 Exceptional items (refer note 4 l 8.10 29.47 5 Profit/(Loss) before tax (3-4) (0.26) 2.21 120;72 1.95 191.76 313.63 6 Tax expenses a) Current tax 26.21 44.36 73.41 b) Current tax • earlier years (13.82) (13.82) 4.69 cl Deferred tax 0.29 0.80 0.22 1.09 0.54 6.82 Total tax expense (netl (13.53) 0.80 26.43 /12.73) 44.90 84.92 7 Net orofit for the oeriod/year/5-6) 13.27 1.41 94.29 14.68 146.86 228.71 8 other comprehensive income/ (loss) 8.a Items that will not be reclassified to profit or loss (i) Gain on remeasurement of defined benefit plan 0.10 0.20 (0.05) 0.30 0.06 2.05 (ii) Income tax relating to items that will not be reclassified to profit or 0.00 (0.05) 0.01 (0.05) (0,02) (0.52) loss 8.b Items that will be reclassified to profit or (i) Effective portion of gain / (loss) on hedging instrument fn a cash flow 1.94 7.87 (8.64) 9.81 (8.6<1) (9.93) hedging (ii) Income tax relating to items that will be reclassified to profit or loss (0.51) (1.98) 2.18 (2.49) 2.18 2.50 Total other comprehensive income/llossl for the period/vear 1.53 6.04 (6.50) 7.57 (6.42) 15.90) 9 Total comorehensfve income for the oeriod/vear 17+8) 14.80 7.45 87.79 22.25 140.44 222.81 10 Paid-up equity share capital 38,26 38.26 38.26 38.26 38.26 38.26 Face Value of the Share ,1.00 ,1.00 ,1.00 ,1.00 ,1.00 ,1.00 11 Other equity 4,441.85 12 Earning Per Share (EPSJ-Face value of ,11-each) a) Basic 0.35 0.04 2.46 0.39 3.84 5.98 b) Diluted 0.34 0.04 2.46 0.38 3.83 5.97 (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) COHANCE LIFESCIENCES LIMITED (formerly known as Suven Pharmaceuticals Limited) Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midco, Mumbai, Mumbai, Maharashtra, India, 400093 "In Crores PART-II CONSOLIDATED For the quarter ended For the Half year ended For the year SI. No. PARTICULARS ended 30 Seotember 2026 30June 2026 30 Sentember 2025 30 Seotember 2026 30 Seotember 2025 31 March 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Income Revenue from operations 476.65 422.26 555.57 898.91 1,104.88 2,268.55 Other income 12.41 12.25 15.60 24.66 29.77 34.09 Total Income 489.06 434.51 571.17 923.57 1 134.65 2 302.64 2 Expenses a) Cost of materials consumed 236.64 158.68 191.60 395.32 369.93 705.39 b) Changes in Inventories of finished goods and work-in-progress (97.55) (38.40) (50.47) (135.95) (80.66) (42.76) c) Employee benefits expense 153.54 132.96 126.72 286.50 260.04 507.71 d) Finance costs 8.37 6.74 8.76 15.11 18.94 37.24 e) Depreciation and amortisation expense 50.17 49.54 44.02 99.71 89.16 187.33 If l Other exoenses 148.64 167.86 166.77 316.50 322.61 671.22 Total expenses 499.81 477.38 487.40 977.19 980.02 2 066.13 3 Profit/(loss) before tax and exceptional items (1-2) (10.75) (42.87) 83.77 (53.62) 154.63 236.51 4 Exceotional items /refer note 41 8.10 29.47 5 Profit/llossl before tax and share of associate 13-41 110.751 142.871 83.77 (53.62} 146.53 207.04 6 Tax expenses a [Showing first 8,000 characters — download PDF for full document]